LIVIVO - Search results -

Search results

Result 1 - 10 of total 616

Search options

Article ; Online: Reply to N.-K.V. Cheung et al.

Matthay, Katherine K / London, Wendy B / Maris, John / Adamson, Peter C / Park, Julie R

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

2014 Volume 32, Issue 36, Page(s) 4174–4175

MeSH term(s)	Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bone Marrow Transplantation ; Humans ; Isotretinoin/therapeutic use ; Neuroblastoma/therapy
Chemical Substances	Isotretinoin (EH28UP18IF)
Language	English
Publishing date	2014-12-20
Publishing country	United States
Document type	Comment ; Letter
ZDB-ID	604914-x
ISSN	1527-7755 ; 0732-183X
ISSN (online)	1527-7755
ISSN	0732-183X
DOI	10.1200/JCO.2014.58.7006
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1847: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 650: Show issues

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article: Decreased expression of both the alpha1- and alpha2-subunits of the Na-K-ATPase reduces maximal alveolar epithelial fluid clearance.

Looney, Mark R / Sartori, Claudio / Chakraborty, Santanu / James, Paul F / Lingrel, Jerry B / Matthay, Michael A

American journal of physiology. Lung cellular and molecular physiology

2005 Volume 289, Issue 1, Page(s) L104–10

Abstract: ... and more severe experimental lung injury, whereas even a small fraction of the normal Na-K-ATPase ... protein expression of the alpha(1)- and/or alpha(2)-subunit of the Na-K-ATPase. There was no difference ... or alpha(2)-subunits of the Na-K-ATPase does not impair basal or stimulated AFC. However, a 50 ...

Abstract	Impaired epithelial sodium channel function predisposes to delayed resorption of pulmonary edema and more severe experimental lung injury, whereas even a small fraction of the normal Na-K-ATPase activity is thought to be sufficient to maintain normal ion transport. However, direct proof is lacking. Therefore, we studied baseline and cAMP stimulated alveolar fluid clearance (AFC) in mice with a 50% decrease in lung protein expression of the alpha(1)- and/or alpha(2)-subunit of the Na-K-ATPase. There was no difference in basal and stimulated AFC in alpha(1)(+/-) or alpha(2)(+/-) mice compared with wild-type littermates. Also, the compound heterozygous mice (alpha(1)(+/-)/alpha(2)(+/-)) had normal basal AFC. However, the combined alpha(1)(+/-)/alpha(2)(+/-) mice showed a significant decrease in cAMP-stimulated AFC compared with wild-type littermates (11.1 +/- 1.0 vs. 14.9 +/- 1.8%/30 min, P < 0.001). When exposed to 96 h of >95% hyperoxia, the decrease in stimulated AFC in the alpha(1)(+/-)/alpha(2)(+/-) mice was not associated with more lung edema compared with wild-type littermates (lung wet-to-dry weight ratio 6.6 +/- 0.9 vs. 5.9 +/- 1.1, respectively; P = not significant). Thus a 50% decrease in protein expression of the alpha(1)- or alpha(2)-subunits of the Na-K-ATPase does not impair basal or stimulated AFC. However, a 50% protein reduction in both the alpha(1)- and alpha(2)-subunits of the Na-K-ATPase produces a submaximal stimulated AFC, suggesting a synergistic role for alpha(1)- and alpha(2)-subunits in cAMP-dependent alveolar epithelial fluid clearance.
MeSH term(s)	Animals ; Biological Transport, Active/physiology ; Cyclic AMP/metabolism ; Epithelial Cells/enzymology ; Extracellular Fluid/metabolism ; Gene Expression Regulation ; Hyperoxia/metabolism ; Mice ; Mice, Knockout ; Pulmonary Alveoli/cytology ; Pulmonary Alveoli/metabolism ; Pulmonary Edema/metabolism ; Sodium-Potassium-Exchanging ATPase/genetics ; Sodium-Potassium-Exchanging ATPase/metabolism
Chemical Substances	Cyclic AMP (E0399OZS9N) ; Atp1a2 protein, mouse (EC 3.6.1.-) ; Sodium-Potassium-Exchanging ATPase (EC 7.2.2.13)
Language	English
Publishing date	2005-03-18
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, P.H.S.
ZDB-ID	1013184-x
ISSN	1522-1504 ; 1040-0605
ISSN (online)	1522-1504
ISSN	1040-0605
DOI	10.1152/ajplung.00464.2004
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uc I Zs.89: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.A 2749: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Advancing therapy for neuroblastoma.

Qiu, Bo / Matthay, Katherine K

Nature reviews. Clinical oncology

2022 Volume 19, Issue 8, Page(s) 515–533

Abstract: Neuroblastomas are tumours of sympathetic origin, with a heterogeneous clinical course ranging from localized or spontaneously regressing to widely metastatic disease. Neuroblastomas recapitulate many of the features of sympathoadrenal development, which ...

Abstract	Neuroblastomas are tumours of sympathetic origin, with a heterogeneous clinical course ranging from localized or spontaneously regressing to widely metastatic disease. Neuroblastomas recapitulate many of the features of sympathoadrenal development, which have been directly targeted to improve the survival outcomes in patients with high-risk disease. Over the past few decades, improvements in the 5-year survival of patients with metastatic neuroblastomas, from <20% to >50%, have resulted from clinical trials incorporating high-dose chemotherapy with autologous stem cell transplantation, differentiating agents and immunotherapy with anti-GD2 monoclonal antibodies. The next generation of trials are designed to improve the initial response rates in patients with high-risk neuroblastomas via the addition of immunotherapies, targeted therapies (such as ALK inhibitors) and radiopharmaceuticals to standard induction regimens. Other trials are focused on testing precision medicine strategies for patients with relapsed and/or refractory disease, enhancing the antitumour immune response and improving the effectiveness of maintenance regimens, in order to prolong disease remission. In this Review, we describe advances in delineating the pathogenesis of neuroblastoma and in identifying the drivers of high-risk disease. We then discuss how this knowledge has informed improvements in risk stratification, risk-adapted therapy and the development of novel therapies.
MeSH term(s)	Antibodies, Monoclonal/pharmacology ; Antibodies, Monoclonal/therapeutic use ; Hematopoietic Stem Cell Transplantation ; Humans ; Immunotherapy/methods ; Neuroblastoma/drug therapy ; Neuroblastoma/pathology ; Transplantation, Autologous
Chemical Substances	Antibodies, Monoclonal
Language	English
Publishing date	2022-05-25
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	2491410-1
ISSN	1759-4782 ; 1759-4774
ISSN (online)	1759-4782
ISSN	1759-4774
DOI	10.1038/s41571-022-00643-z
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6029: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MG 103: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Interleukin 2 plus anti-GD2 immunotherapy: helpful or harmful?

Matthay, Katherine K

The Lancet. Oncology

2018 Volume 19, Issue 12, Page(s) 1549–1551

MeSH term(s)	Antibodies, Monoclonal ; Humans ; Immunotherapy ; Interleukin-2 ; Neuroblastoma ; Proteins
Chemical Substances	Antibodies, Monoclonal ; Interleukin-2 ; NBL1 protein, human ; Proteins ; ch14.18 monoclonal antibody (7SQY4ZUD30)
Language	English
Publishing date	2018-11-12
Publishing country	England
Document type	Journal Article ; Comment
ZDB-ID	2049730-1
ISSN	1474-5488 ; 1470-2045
ISSN (online)	1474-5488
ISSN	1470-2045
DOI	10.1016/S1470-2045(18)30627-2
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5696: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 460: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Neuroblastoma: clinical and biological approach to risk stratification and treatment.

Tolbert, Vanessa P / Matthay, Katherine K

Cell and tissue research

2018 Volume 372, Issue 2, Page(s) 195–209

Abstract: Neuroblastoma is the most common extra-cranial solid tumor of childhood and the most common in the first year of life. It is a unique malignancy in that infants often present with either localized or metastatic disease that can spontaneously regress ... ...

Abstract	Neuroblastoma is the most common extra-cranial solid tumor of childhood and the most common in the first year of life. It is a unique malignancy in that infants often present with either localized or metastatic disease that can spontaneously regress without intervention while older children can succumb to the disease after months to years of arduous therapy. Given this wide range of outcomes, the International Neuroblastoma Risk Group was created to stratify patients based on presenting characteristics and tumor biology in order to guide intensity of treatment strategies. The goal has been to decrease therapy for low-risk patients to avoid long-term complications while augmenting and targeting therapies for high-risk patients to improve overall survival. The international risk stratification depends on age, stage, histology, MYCN gene amplification status, tumor cell ploidy and segmental chromosomal abnormalities. Treatment for asymptomatic low-risk patients with an estimated survival of > 98% is often observation or surgical resection alone, whereas intermediate-risk patients with an estimated survival of > 90% require moderate doses of response-adjusted chemotherapy along with resection. High-risk patients undergo multiple cycles of combination chemotherapy before surgery, followed by consolidation with myeloablative autologous hematopoietic stem cell transplantation and local radiation and finally immunotherapy with differentiation therapy as maintenance phase. With this approach, outcome for patients with neuroblastoma has improved, as the field continues to expand efforts in more targeted therapies for high-risk patients.
MeSH term(s)	Disease-Free Survival ; Early Detection of Cancer ; Humans ; Neoplasm Staging ; Neuroblastoma/pathology ; Neuroblastoma/therapy ; Risk Assessment ; Risk Factors
Language	English
Publishing date	2018-03-23
Publishing country	Germany
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	125067-x
ISSN	1432-0878 ; 0302-766X
ISSN (online)	1432-0878
ISSN	0302-766X
DOI	10.1007/s00441-018-2821-2
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Ub I Zs.94: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Corticosteroids, COVID-19 pneumonia and acute respiratory distress syndrome

Matthay, M. A. / Wick, K. D.

J Clin Invest

Abstract: While corticosteroids dampen the dysregulated immune system and sometimes are prescribed as an adjunctive treatment for pneumonia, their effectiveness in the treatment of coronavirus 2019 (COVID-19) remains controversial In this issue of the JCI, Liu and ...

Abstract	While corticosteroids dampen the dysregulated immune system and sometimes are prescribed as an adjunctive treatment for pneumonia, their effectiveness in the treatment of coronavirus 2019 (COVID-19) remains controversial In this issue of the JCI, Liu and Zhang et al evaluated corticosteroid treatment in more than 400 patients with severe COVID-19 The authors assessed subjects retrospectively for cardiac and liver injury, shock, ventilation, mortality, and viral clearance Corticosteroids in severe COVID-19 related acute respiratory distress syndrome (ARDS) was associated with increased mortality and delayed viral clearance Here, we consider how to reconcile the negative effects of corticosteroids revealed by Liu and Zhang et al with the favorable effects (reduced mortality) that were described in the RECOVERY trial We posit that treatment timing, dosage, and COVID-19 disease severity determine immune response and viral outcome Patients with moderate-to-severe COVID-19 pneumonia are likely to benefit from moderate dose corticosteroid treatment when administered relatively late in the disease course
Keywords	covid19
Publisher	WHO
Document type	Article
Note	WHO #Covidence: #798370
Database	COVID19

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Article: Aurora Kinase A inhibition enhances DNA damage and tumor cell death with

Kumar, Prerna / Koach, Jessica / Nekritz, Erin / Mukherjee, Sucheta / Braun, Benjamin S / DuBois, Steven G / Nasholm, Nicole / Haas-Kogan, Daphne / Matthay, Katherine K / Weiss, William A / Gustafson, Clay / Seo, Youngho

Research square

2024

Abstract: Background: Neuroblastoma is the most common extra-cranial pediatric solid tumor. : Results: Using an : Conclusion: The combination of AURKA inhibition ... ...

Abstract	Background: Neuroblastoma is the most common extra-cranial pediatric solid tumor. Results: Using an Conclusion: The combination of AURKA inhibition with
Language	English
Publishing date	2024-01-18
Publishing country	United States
Document type	Preprint
DOI	10.21203/rs.3.rs-3845114/v1
Database	MEDical Literature Analysis and Retrieval System OnLINE

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Article ; Online: Targeted isotretinoin in neuroblastoma: kinetics, genetics, or absorption.

Matthay, Katherine K

Clinical cancer research : an official journal of the American Association for Cancer Research

2012 Volume 19, Issue 2, Page(s) 311–313

Abstract: Isotretinoin (13-cis-retinoic acid; 13-cisRA) has been shown to significantly improve survival for children with high-risk neuroblastoma. Pharmacokinetics of isotretinoin may be negatively affected by the mode of drug administration and the dosing ... ...

Abstract	Isotretinoin (13-cis-retinoic acid; 13-cisRA) has been shown to significantly improve survival for children with high-risk neuroblastoma. Pharmacokinetics of isotretinoin may be negatively affected by the mode of drug administration and the dosing formula.
MeSH term(s)	Antineoplastic Agents/administration & dosage ; Female ; Humans ; Isotretinoin/administration & dosage ; Male ; Neuroblastoma/drug therapy
Chemical Substances	Antineoplastic Agents ; Isotretinoin (EH28UP18IF)
Language	English
Publishing date	2012-12-03
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Comment
ZDB-ID	1225457-5
ISSN	1557-3265 ; 1078-0432
ISSN (online)	1557-3265
ISSN	1078-0432
DOI	10.1158/1078-0432.CCR-12-3313
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4223: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Congenital malformation syndromes associated with peripheral neuroblastic tumors: A systematic review.

Sznewajs, Aimee / Pon, Elizabeth / Matthay, Katherine K

Pediatric blood & cancer

2019 Volume 66, Issue 10, Page(s) e27901

Abstract: Malformation syndromes with predisposition to peripheral neuroblastic tumors (pNT), including neuroblastoma, ganglioneuroblastoma, and ganglioneuroma, may provide clues to critical mutations influencing pNT development. Our objective was to identify and ... ...

Abstract	Malformation syndromes with predisposition to peripheral neuroblastic tumors (pNT), including neuroblastoma, ganglioneuroblastoma, and ganglioneuroma, may provide clues to critical mutations influencing pNT development. Our objective was to identify and characterize features of pNT associated with specific malformation syndromes. A systematic review of the literature was performed using MEDLINE, Scopus, and Web of Science. We identified 154 of 1014 papers that met eligibility, comprising 207 cases. The patient's age, tumor histology, and frequency of multiple primary tumors varied by malformation syndrome. Genomic studies and systematized reporting are necessary to elucidate cancer risk and the distinct clinical and biological pNT patterns within syndromes.
MeSH term(s)	Congenital Abnormalities ; Ganglioneuroma/etiology ; Humans ; Neuroblastoma/etiology ; Syndrome
Language	English
Publishing date	2019-07-02
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Systematic Review
ZDB-ID	2131448-2
ISSN	1545-5017 ; 1545-5009
ISSN (online)	1545-5017
ISSN	1545-5009
DOI	10.1002/pbc.27901
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1131: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Association of SARS-CoV-2 nucleocapsid viral antigen and the receptor for advanced glycation end products with development of severe disease in patients presenting to the emergency department with COVID-19.

Matthay, Zachary A / Fields, Alexander T / Wick, Katherine D / Jones, Chayse / Lane, H Clifford / Herrera, Kimberly / Nuñez-Garcia, Brenda / Gennatas, Efstathios / Hendrickson, Carolyn M / Kornblith, Aaron E / Matthay, Michael A / Kornblith, Lucy Z

Frontiers in immunology

2023 Volume 14, Page(s) 1130821

Abstract: Introduction: There remains a need to better identify patients at highest risk for developing severe Coronavirus Disease 2019 (COVID-19) as additional waves of the pandemic continue to impact hospital systems. We sought to characterize the association ... ...

Abstract	Introduction: There remains a need to better identify patients at highest risk for developing severe Coronavirus Disease 2019 (COVID-19) as additional waves of the pandemic continue to impact hospital systems. We sought to characterize the association of receptor for advanced glycation end products (RAGE), SARS-CoV-2 nucleocapsid viral antigen, and a panel of thromboinflammatory biomarkers with development of severe disease in patients presenting to the emergency department with symptomatic COVID-19. Methods: Blood samples were collected on arrival from 77 patients with symptomatic COVID-19, and plasma levels of thromboinflammatory biomarkers were measured. Results: Differences in biomarkers between those who did and did not develop severe disease or death 7 days after presentation were analyzed. After adjustment for multiple comparisons, RAGE, SARS-CoV-2 nucleocapsid viral antigen, interleukin (IL)-6, IL-10 and tumor necrosis factor receptor (TNFR)-1 were significantly elevated in the group who developed severe disease (all Discussion: Elevated RAGE and SARS-CoV-2 nucleocapsid viral antigen on emergency department presentation are strongly associated with development of severe disease at 7 days. These findings are of clinical relevance for patient prognostication and triage as hospital systems continue to be overwhelmed. Further studies are warranted to determine the feasibility and utility of point-of care measurements of these biomarkers in the emergency department setting to improve patient prognostication and triage.
MeSH term(s)	Humans ; COVID-19 ; SARS-CoV-2 ; Receptor for Advanced Glycation End Products ; Nucleocapsid ; Antigens ; Biomarkers ; Antigens, Viral
Chemical Substances	Receptor for Advanced Glycation End Products ; Antigens ; Biomarkers ; Antigens, Viral
Language	English
Publishing date	2023-03-21
Publishing country	Switzerland
Document type	Journal Article ; Research Support, N.I.H., Extramural
ZDB-ID	2606827-8
ISSN	1664-3224 ; 1664-3224
ISSN (online)	1664-3224
ISSN	1664-3224
DOI	10.3389/fimmu.2023.1130821
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito